Research

Unseen Adversaries: The Critical Impact of Airborne Pathogens on Healthcare Safety and Economics

A LifeAire Systems white paper examining the critical impact of airborne pathogens on healthcare safety and economics. The paper reviews the $28.4 billion annual cost of healthcare-associated infections in the United States, the limitations of HEPA filtration as a capture-only strategy that does not neutralize pathogens or eliminate VOCs, and the paradigm shift represented by ASHRAE 241: Control of Infectious Aerosols — which establishes new standards for single-pass pathogen inactivation that LifeAire’s technology meets and surpasses. The paper presents comparative environmental data showing 1,778 cfu/m3 viable biological pathogens and 1,372 ppb chemical contamination in HEPA-only clinical environments versus less than 1 cfu/m3 biological and less than 100 ppb chemical in HEPA plus LifeAire-purified environments. Includes study design details from the St. Luke’s Allentown 12-month hospital study, long-term care outcomes, and ASHRAE publication references. Published by LifeAire Systems, 2026.

Research

LifeAire Systems protected memory support floor over 15 months and delivered 39.6% reduction in facility-acquired infections

A LifeAire Systems case summary presenting key outcomes from the 15-month IRB-approved study of LifeAire’s advanced air purification technology in a memory support long-term care facility. The study compared a LifeAire-protected floor with a HEPA-only control floor in the same facility. Documented outcomes in the LifeAire-protected unit included an 89.1% reduction in airborne pathogens, an 88.9% reduction in surface pathogens, a 39.6% reduction in facility-acquired infections, and a 47% reduction in staff call-outs. The findings demonstrate that continuous air purification delivers measurable improvements in resident health, staff wellbeing, and facility economics in long-term care and memory support environments. The underlying peer-reviewed data was published in The Journals of Gerontology: Series A, 2023. Published by LifeAire Systems, January 2026.

Research

LifeAire Systems protected 14 patient rooms over 12 months and delivered $2.3M in savings

A LifeAire Systems case summary presenting the financial and clinical outcomes from a 12-month air purification study conducted at St. Luke’s University Health Network in Allentown, Pennsylvania. LifeAire’s advanced air purification system was installed in a 14-room medical-surgical unit and compared against a matched HEPA-only control unit across 8,255 patients. Documented outcomes included a 99.99% reduction in viable airborne pathogens, a 97% reduction in surface pathogens, a 39.5% reduction in patient length of stay, a trending reduction in hospital-acquired infections, and $2.3 million in total documented savings in a single year from a system costing less than $125,000 fully installed. The underlying peer-reviewed data was published in the journal Surgery, September 2020. Published by LifeAire Systems, January 2026.

Research

Aire~IRMU™ – VOC Removal Testing Data

Independent third-party testing data documenting the volatile organic compound removal performance of the LifeAire Aire~IRMU In-Room Modular Air Purification Unit. The Aire~IRMU delivers LifeAire’s proven multi-stage purification technology — including molecular media VOC neutralization, UV pathogen kill, and HEPA filtration — in a compact, plug-and-play format requiring no HVAC integration. This testing data validates the VOC remediation capability of the Aire~IRMU for facilities and clinical environments where in-duct systems are not practical, including patient rooms, clinic spaces, senior living environments, and IVF laboratories. Published by LifeAire Systems, January 2026.